Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

TRGNY

Transgene . (TRGNY)

Transgene S.A. ADS (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TRGNY
DataHoraFonteTítuloCódigoCompanhia
19/10/200504:00PR Newswire (US)Transgene : Cash Position and Net Cash Expenditures as of September 30, 2005NASDAQ:TRGNY
21/09/200502:01PR Newswire (US)Transgene to Voluntarily Delist From NasdaqNASDAQ:TRGNY
03/08/200502:01PR Newswire (US)Transgene Announces First Half 2005 Financial ResultsNASDAQ:TRGNY
21/07/200502:01PR Newswire (US)Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene's Proprietary TechnologyNASDAQ:TRGNY
11/07/200514:01PR Newswire (US)Transgene Raises Euro 34.9 MillionNASDAQ:TRGNY
20/05/200502:01PR Newswire (US)Transgene Announces 20-F Form FilingNASDAQ:TRGNY
17/05/200502:01PR Newswire (US)Transgene's Therapeutic Vaccine MVA-MUC1-IL2 at ASCO:NASDAQ:TRGNY
16/05/200502:01PR Newswire (US)Transgene Presents Updated Positive Phase II Data of Its Therapeutic Vaccine MVA-MUC1-IL2 In Prostate Cancer at Annual ASCO MeetNASDAQ:TRGNY
26/04/200502:01PR Newswire (US)Transgene to Present at the 2nd Rodman & Renshaw Annual Global Healthcare ConferenceNASDAQ:TRGNY
13/04/200502:01PR Newswire (US)Transgene: Cash Position and Net Cash Expenditures as of March 31, 2005NASDAQ:TRGNY
05/04/200502:01PR Newswire (US)Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual MeetingNASDAQ:TRGNY
23/02/200503:00PR Newswire (US)Transgene Announces Fiscal Year 2004 Financial ResultsNASDAQ:TRGNY
23/02/200503:00PR Newswire (US)Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 Meets Primary Endpoint in Lung Cancer Phase IINASDAQ:TRGNY
15/02/200503:01PR Newswire (US)Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific OfficerNASDAQ:TRGNY
08/12/200403:01PR Newswire (US)Transgene Appoints Philippe Archinard As New Chief Executive OfficerNASDAQ:TRGNY
30/11/200414:34PR Newswire (US)Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical LesionsNASDAQ:TRGNY
03/11/200403:01PR Newswire (US)Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004NASDAQ:TRGNY
04/08/200402:01PR Newswire (US)Transgene Announces Second Quarter and First Half 2004 Financial ResultsNASDAQ:TRGNY
01/07/200410:31PR Newswire (US)Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC ProjectNASDAQ:TRGNY
15/06/200403:00PR Newswire (US)Merial and Transgene Sign a Collaboration Agreement to Develop Products for Animal HealthNASDAQ:TRGNYTransgene S.A. ADS (MM)
08/06/200402:01PR Newswire (US)Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual MeetingsNASDAQ:TRGNY
12/05/200410:45PR Newswire (US)Transgene to Present Data at 2004 ASCO Annual MeetingNASDAQ:TRGNY
05/05/200402:01PR Newswire (US)Transgene Announces First Quarter 2004 Financial ResultsNASDAQ:TRGNY
14/04/200402:01PR Newswire (US)Transgene: Data Presented at The American Association of Cancer Research Annual Meeting Suggest Significant Opportunities for AnNASDAQ:TRGNY
18/03/200402:01PR Newswire (US)Transgene's MVA-HPV-IL2 Vaccine Shows Activity in Phase II Clinical TrialNASDAQ:TRGNY
11/02/200403:01PR Newswire (US)Transgene Announces Fourth Quarter and Fiscal Year 2003 Financial ResultsNASDAQ:TRGNY
09/02/200403:00PR Newswire (US)Transgene Reports Positive Interim Phase II Data from MVA-Muc1-IL2 Cancer Vaccine ProgramNASDAQ:TRGNY
05/11/200303:01PR Newswire (US)Transgene Announces Third Quarter 2003 Financial ResultsNASDAQ:TRGNY
03/11/200303:01PR Newswire (US)Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERMNASDAQ:TRGNY
 Apresentando as notícias mais relevantes sobre:NASDAQ:TRGNY